OBJECTIVE: Our goal is to determine if antimicrobial prophylaxis with trimethoprim/sulfamethoxazole prevents recurrent urinary tract infections and renal scarring in children who are found to have vesicoureteral reflux after a first or second urinary tract infection. DESIGN, PARTICIPANTS, AND METHODS: The Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR) study is a double-blind, randomized, placebo-controlled trial. Six hundred children aged 2 to 72 months will be recruited from both primary and subspecialty care settings at clinical trial centers throughout North America. Children who are found to have grades I to IV vesicoureteral reflux after the index febrile or symptomatic urinary tract infection will be randomly assigned to receive daily doses of either trimethoprim/sulfamethoxazole or placebo for 2 years. Scheduled follow-up contacts include in-person study visits every 6 months and telephone interviews every 2 months. Biospecimens (urine and blood) and genetic specimens (blood) will be collected for future studies of the genetic and biochemical determinants of vesicoureteral reflux, recurrent urinary tract infection, renal insufficiency, and renal scarring. RESULTS: The primary outcome is recurrence of urinary tract infection. Secondary outcomes include time to recurrent urinary tract infection, renal scarring (assessed by dimercaptosuccinic acid scan), treatment failure, renal function, resource utilization, and development of antimicrobial resistance in stool flora. CONCLUSIONS: The RIVUR study will provide useful information to clinicians about the risks and benefits of prophylactic antibiotics for children who are diagnosed with vesicoureteral reflux after a first or second urinary tract infection. The data and specimens collected over the course of the study will allow researchers to better understand the pathophysiology of recurrent urinary tract infection and its sequelae.
RCT Entities:
OBJECTIVE: Our goal is to determine if antimicrobial prophylaxis with trimethoprim/sulfamethoxazole prevents recurrent urinary tract infections and renal scarring in children who are found to have vesicoureteral reflux after a first or second urinary tract infection. DESIGN, PARTICIPANTS, AND METHODS: The Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR) study is a double-blind, randomized, placebo-controlled trial. Six hundred children aged 2 to 72 months will be recruited from both primary and subspecialty care settings at clinical trial centers throughout North America. Children who are found to have grades I to IV vesicoureteral reflux after the index febrile or symptomatic urinary tract infection will be randomly assigned to receive daily doses of either trimethoprim/sulfamethoxazole or placebo for 2 years. Scheduled follow-up contacts include in-person study visits every 6 months and telephone interviews every 2 months. Biospecimens (urine and blood) and genetic specimens (blood) will be collected for future studies of the genetic and biochemical determinants of vesicoureteral reflux, recurrent urinary tract infection, renal insufficiency, and renal scarring. RESULTS: The primary outcome is recurrence of urinary tract infection. Secondary outcomes include time to recurrent urinary tract infection, renal scarring (assessed by dimercaptosuccinic acid scan), treatment failure, renal function, resource utilization, and development of antimicrobial resistance in stool flora. CONCLUSIONS: The RIVUR study will provide useful information to clinicians about the risks and benefits of prophylactic antibiotics for children who are diagnosed with vesicoureteral reflux after a first or second urinary tract infection. The data and specimens collected over the course of the study will allow researchers to better understand the pathophysiology of recurrent urinary tract infection and its sequelae.
Authors: H Liu; C E Golin; L G Miller; R D Hays; C K Beck; S Sanandaji; J Christian; T Maldonado; D Duran; A H Kaplan; N S Wenger Journal: Ann Intern Med Date: 2001-05-15 Impact factor: 25.391
Authors: Brunello L Mazzola; Rodo O von Vigier; Sabine Marchand; Martin Tönz; Mario G Bianchetti Journal: J Nephrol Date: 2003 Jan-Feb Impact factor: 3.902
Authors: Nader Shaikh; Alejandro Hoberman; Barbara Wise; Marcia Kurs-Lasky; Diana Kearney; Stephanie Naylor; Mary Ann Haralam; D K Colborn; Steven G Docimo Journal: Pediatrics Date: 2003-11 Impact factor: 7.124
Authors: C William Schwab; Hsi-Yang Wu; Heather Selman; Grahame H H Smith; Howard M Snyder; Douglas A Canning Journal: J Urol Date: 2002-12 Impact factor: 7.450
Authors: Patrick H Conway; Avital Cnaan; Theoklis Zaoutis; Brandon V Henry; Robert W Grundmeier; Ron Keren Journal: JAMA Date: 2007-07-11 Impact factor: 56.272
Authors: Nader Shaikh; Timothy R Shope; Alejandro Hoberman; Gysella B Muniz; Sonika Bhatnagar; Andrew Nowalk; Robert W Hickey; Marian G Michaels; Diana Kearney; Howard E Rockette; Martin Charron; Ruth Lim; Massoud Majd; Eglal Shalaby-Rana; Marcia Kurs-Lasky; Daniel M Cohen; Ellen R Wald; Greg Lockhart; Hans G Pohl; Judith M Martin Journal: Pediatr Nephrol Date: 2020-06-15 Impact factor: 3.714
Authors: Tej K Mattoo; Steven J Skoog; Lisa Gravens-Mueller; Russell W Chesney; Alejandro Hoberman; Ranjiv Mathews; Marva Moxey-Mims; Anastasia Ivanova; Saul P Greenfield; Myra A Carpenter Journal: J Pediatr Urol Date: 2017-06-01 Impact factor: 1.830
Authors: Rachel E Selekman; Daniel J Shapiro; John Boscardin; Gabrielle Williams; Jonathan C Craig; Per Brandström; Marco Pennesi; Gwenalle Roussey-Kesler; Pankaj Hari; Hillary L Copp Journal: Pediatrics Date: 2018-07 Impact factor: 7.124
Authors: Stacy T Tanaka; Pangaja Paramsothy; Judy Thibadeau; John S Wiener; David B Joseph; Earl Y Cheng; Duong Tu; Christopher Austin; Chester J Koh; M Chad Wallis; William O Walker; Kathryn A Smith; Jonathan C Routh; Michelle A Baum Journal: J Urol Date: 2019-06 Impact factor: 7.450